@article{article, title  = {{Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial}},

 publisher = {{Elsevier BV}},

 url = {{}},

 year = {{2021}},

 month = {{7}},

 author = {{Powles T and Csőszi T and Özgüroğlu M and Matsubara N and Géczi L and Cheng SY-S and Fradet Y and Oudard S and Vulsteke C and Morales Barrera R and Fléchon A et al}},

 doi = {{10.1016/s1470-2045(21)00152-2}},

 volume = {{22}},

 journal = {{The Lancet Oncology}},

 issue = {{7}},

 pages = {{931-945}},

 note = {{Accessed on 2024/12/22}}}